- Home
- SMBK vs CGEM Comparison
SMBK vs CGEM Comparison
Compare SMBK & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- CGEM
- Stock Information
- Founded
- SMBK N/A
- CGEM 2016
- Country
- SMBK United States
- CGEM United States
- Employees
- SMBK N/A
- CGEM N/A
- Industry
- SMBK Major Banks
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- SMBK Finance
- CGEM Health Care
- Exchange
- SMBK Nasdaq
- CGEM Nasdaq
- Market Cap
- SMBK 602.3M
- CGEM 482.7M
- IPO Year
- SMBK N/A
- CGEM 2021
- Fundamental
- Price
- SMBK $36.84
- CGEM $6.45
- Analyst Decision
- SMBK Buy
- CGEM Strong Buy
- Analyst Count
- SMBK 4
- CGEM 8
- Target Price
- SMBK $37.25
- CGEM $27.25
- AVG Volume (30 Days)
- SMBK 47.3K
- CGEM 525.8K
- Earning Date
- SMBK 10-20-2025
- CGEM 11-06-2025
- Dividend Yield
- SMBK 0.87%
- CGEM N/A
- EPS Growth
- SMBK 62.51
- CGEM N/A
- EPS
- SMBK 2.47
- CGEM N/A
- Revenue
- SMBK $178,959,000.00
- CGEM N/A
- Revenue This Year
- SMBK $22.86
- CGEM N/A
- Revenue Next Year
- SMBK $10.59
- CGEM N/A
- P/E Ratio
- SMBK $14.93
- CGEM N/A
- Revenue Growth
- SMBK 20.51
- CGEM N/A
- 52 Week Low
- SMBK $26.31
- CGEM $6.44
- 52 Week High
- SMBK $37.72
- CGEM $18.62
- Technical
- Relative Strength Index (RSI)
- SMBK 55.94
- CGEM 36.01
- Support Level
- SMBK $36.52
- CGEM $6.44
- Resistance Level
- SMBK $37.60
- CGEM $7.82
- Average True Range (ATR)
- SMBK 0.63
- CGEM 0.43
- MACD
- SMBK -0.04
- CGEM -0.11
- Stochastic Oscillator
- SMBK 39.29
- CGEM 4.55
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.